Fresh2 Group's revenue for the
three
months ended in Jun. 2023 was $0.00 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $1.73 Mil.
Fresh2 Group's Revenue per Share for the
three
months ended in Jun. 2023 was $0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $1.01.
Warning Sign:
Fresh2 Group Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Fresh2 Group was -83.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -33.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -2.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 6 years, Fresh2 Group's highest 3-Year average Revenue per Share Growth Rate was 53.80% per year. The lowest was -33.90% per year. And the median was 16.00% per year.
Fresh2 Group Revenue Historical Data
The historical data trend for Fresh2 Group's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fresh2 Group's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresh2 Group's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fresh2 Group's Revenue distribution charts can be found below:
* The bar in red indicates where Fresh2 Group's Revenue falls into.
Fresh2 Group Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresh2 Group (NAS:FRES) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Fresh2 Group Revenue Related Terms
Thank you for viewing the detailed overview of Fresh2 Group's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRES has been successfully added to your 